Article Sidebar

PDF
Date Published: 23/12/2021
Abstract Views: 122
Views PDF: 178
DOI: https://doi.org/10.51298/vmj.v507i2.1435
Issue
Vol. 507 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Phương Anh, N. ., & Hùng Kiên, Đỗ . (2021). EFFICACY OF GEMCITABINE –CISPLATIN IN METASTATIC NASOPHARYNGEAL CANCER PATIENTS IN VIETNAM NATIONAL CANCER HOSPITAL. Vietnam Medical Journal, 507(2). https://doi.org/10.51298/vmj.v507i2.1435

EFFICACY OF GEMCITABINE –CISPLATIN IN METASTATIC NASOPHARYNGEAL CANCER PATIENTS IN VIETNAM NATIONAL CANCER HOSPITAL

Nguyễn Thị Phương Anh1,, Đỗ Hùng Kiên2
1 Hanoi Medical University
2 Tân Triều Brach of National Cancer Hospital

Main Article Content

Abstract

Objectives: The aims of our study were to investigate the activity and toxicity of gemcitabine – cisplatin regimen in metastatic nasopharyngeal cancer patients. Patients and Methods: Clinical trial, retrospective study. From January 2018 to July 2021, we enrolled 33 metastatic nasopharyngeal cancer patientsin Vietnam National Cancer Hospital. All patients received combination of gemcitabine and cisplatin. Tumor response rateand toxicitys were determined.  Results: Response rate: Overal response rate was 83,9%. Median progression free survival was 8,9 months. Toxicity: Most adverse events were manageable and tolerable. The most common was neutropenia (60.6%), anaemia (90.9%), vomiting and nausea (51.5%), most of them were grade 1 and grade 2. Conclusion: Gemcitabine – cisplatin regimen in metastatic nasopharyngeal cancer patients is high repsond rate and tolerable.

Article Details

Keywords

Nasopharyngeal cancer, recurrent, metastatic stages

References

1. Sung H., Ferlay J., Siegel R.L. và cộng sự. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin, 71(3), 209–249.
2. Lê Văn Quảng Ung thư vòm mũi họng. Ung thư đầu cổ. Nhà xuất bản Y học, 190–211.
3. Feng B.-J. (2013). Descriptive, Environmental and Genetic Epidemiology of Nasopharyngeal Carcinoma. Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology. Springer, New York, NY, 23–41.
4. Ong Y.K., Heng D.M., Chung B. và cộng sự. (2003). Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer, 39(11), 1535–1541.
5. Toh C.-K., Heng D., Ong Y.-K. và cộng sự. (2005). Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer, 92(8), 1382–1387.
6. Zhang L., Huang Y., Hong S. và cộng sự. (2016). Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet, 388(10054), 1883–1892.
7. Eisenhauer E.A., Therasse P., Bogaerts J. và cộng sự. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247.
8. Jiang Y., Wei Y., Luo F. và cộng sự. (2005). Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma: A Pilot Study. Cancer Investigation, 23(2), 123–128.
9. Hsieh J.C.-H., Hsu C.-L., Ng S.-H. và cộng sự. (2015). Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Jpn J Clin Oncol, 45(9), 819–827.